Latest Research And Development News

Adisyn Ltd has successfully raised $10 million through a heavily oversubscribed placement, signaling strong institutional confidence in its graphene-enhanced semiconductor technology. The capital will accelerate development, commercial partnerships, and operational scaling.

Galilee Energy reports a $1.9 million R&D tax refund and terminates its merger with Vintage Energy, while maintaining steady progress at its Glenaras Gas Project and a robust cash position of $4.38 million.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

Australian Silica Quartz Group reports promising gold intersections at Koolyanobbing Metals Project and progresses its Quartz Hill silica project with positive metallurgical results and strategic funding.

VHM Limited has secured ministerial endorsement for its Goschen Project Environmental Effects Statement, paving the way for a Final Investment Decision and targeted production in 2026. The company also advanced financing and strategic appointments to support its development trajectory.

Raptis Group Limited reported a positive net cash inflow from operating activities of $54,509 for the quarter ended December 31, 2024, ending with $303,102 in cash and equivalents. The company recorded no investing or financing cash flows during the period.

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.

Nyrada Inc. reports promising preclinical results for its lead drug NYR-BI03, showing an 86% cardioprotective effect, alongside a strong financial position bolstered by a AU$3.29 million capital raise. The company has submitted its Phase Ia clinical trial package, setting the stage for human testing.

Talius Group reports a robust December quarter with $4.4 million revenue, positive operating cash flow, and a strategic $2.5 million capital raise, positioning the company for strong growth in 2025 amid evolving aged care legislation.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

BPH Global has completed its acquisition of Indonesian seaweed assets, establishing a wholly owned subsidiary and launching joint operations aimed at expanding seaweed cultivation and bio-stimulant product development across Asia.